

INVERNESS MEDICAL INNOVATIONS INC  
Form 8-K  
October 07, 2004

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) October 7, 2004**

**Inverness Medical Innovations, Inc.**  
(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-16789**  
(Commission file number)

**04-3565120**  
(IRS Employer Identification  
No.)

**51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453**  
(Address of principal executive offices)

Registrant's telephone number, including area code: **(781) 647-3900**

**Not Applicable**

(Former name or former address, if changed since last report)

## Edgar Filing: INVERNESS MEDICAL INNOVATIONS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 8.01 OTHER EVENTS**

A copy of our press release entitled Inverness Medical Innovations Updates Acon Laboratories Litigation, dated October 7, 2004 is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

c)

Exhibits. The following exhibits are filed with this document.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated October 7, 2004, entitled Inverness Medical Innovations Updates Acon Laboratories Litigation

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVERNESS MEDICAL INNOVATIONS, INC.

BY:                    /s/ Jay McNamara  
                             Jay McNamara  
                             Associate General Counsel & Assistant  
                             Secretary

Dated: October 7, 2004

**EXHIBIT INDEX**

**Exhibit  
Number**

**Description**

99.1 Press Release dated October 7, 2004 entitled Inverness Medical Innovations Updates Acon Laboratories Litigation